We're excited to share our 'Reflect' Reconciliation Action Plan

We have released our 2023 Annual Report Click here to read the Annual Report →

We're Bigger and Better Than Ever!

CSL Behring is a proud part of the CSL family, which includes CSL Seqirus and CSL Vifor.

Learn More About Us

Our Focus on Rare & Serious Diseases

Our portfolio of innovative medicines includes a range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and other serious and rare diseases in the areas of: - Immunology - Haematology and thrombosis - Transplant - Neurology - Cardiovascular and metabolic disease - Respiratory and critical care

Learn More

We Offer Promising FUTURES

Join a global biotech leader. We’re ready for you!

Learn More About Careers at CSL Behring

Image of the Aboriginal Artwork which appears on the front cover of CSL's Reflection Reconciliation Action Plan document. Artwork provided by Simone Thomson in collaboration with Dreamtime Art Creative Consultancy.

Acknowledgement of Country

We acknowledge Traditional Owners of Country throughout Australia and recognise their continuing connection to lands, waters and communities. We pay our respects to all Aboriginal and Torres Strait Islander cultures; and to Elders past and present.

We're excited to share our 'Reflect' Reconciliation Action Plan

We're Bigger and Better Than Ever!

Our Focus on Rare & Serious Diseases

We Offer Promising FUTURES

Acknowledgement of Country

Learn More About CSL’s Reconciliation Action Plan